Matinas BioPharma Holdings Inc. [AMEX: MTNB] loss -5.66% or -0.06 points to close at $1.00 with a heavy trading volume of 2546444 shares. The company report on December 1, 2020 that Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer.
– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules –.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, announced the appointment of Hui Liu, Ph.D., M.B.A. as Chief Technology Officer. Dr. Liu joins Matinas with extensive experience in pharmaceutical formulation and delivery technologies, including lipid nanoparticle formulations of mRNA, siRNA and vaccines. In this new role, Dr. Liu will work closely with Raphael Mannino, Ph.D., Matinas’ Chief Scientific Officer, and lead efforts to further strengthen the Company’s proprietary lipid nanocrystal (LNC) drug delivery platform and accelerate its potential applications for both internal programs and external collaborations.
It opened the trading session at $1.06, the shares rose to $1.06 and dropped to $0.95, the range by which the price of stock traded the whole day. The daily chart for MTNB points out that the company has recorded 16.27% gains over the past six months. However, it is still -104.08% lower than its most recent low trading price.
If we look at the average trading volume of 1.71M shares, MTNB reached to a volume of 2546444 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Matinas BioPharma Holdings Inc. [MTNB]:
Piper Sandler have made an estimate for Matinas BioPharma Holdings Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 26, 2020. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on January 27, 2020, representing the official price target for Matinas BioPharma Holdings Inc. stock.
The Average True Range (ATR) for Matinas BioPharma Holdings Inc. is set at 0.07, with the Price to Sales ratio for MTNB stock in the period of the last 12 months amounting to 1784.88. The Price to Book ratio for the last quarter was 3.13, with the Price to Cash per share for the same quarter was set at 0.37.
Trading performance analysis for MTNB stock
Matinas BioPharma Holdings Inc. [MTNB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.48. With this latest performance, MTNB shares gained by 21.95% in over the last four-week period, additionally plugging by 16.27% over the last 6 months – not to mention a drop of -26.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MTNB stock in for the last two-week period is set at 64.42, with the RSI for the last a single of trading hit 65.10, and the three-weeks RSI is set at 62.13 for Matinas BioPharma Holdings Inc. [MTNB]. The present Moving Average for the last 50 days of trading for this stock 0.8473, while it was recorded at 1.0163 for the last single week of trading, and 0.8109 for the last 200 days.
Matinas BioPharma Holdings Inc. [MTNB]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Matinas BioPharma Holdings Inc. [MTNB] shares currently have an operating margin of -21067.38. Matinas BioPharma Holdings Inc.’s Net Margin is presently recorded at -19343.35.
Return on Total Capital for MTNB is now -70.32, given the latest momentum, and Return on Invested Capital for the company is -65.49. Return on Equity for this stock declined to -70.63, with Return on Assets sitting at -57.73. When it comes to the capital structure of this company, Matinas BioPharma Holdings Inc. [MTNB] has a Total Debt to Total Equity ratio set at 12.79. Additionally, MTNB Total Debt to Total Capital is recorded at 11.34, with Total Debt to Total Assets ending up at 10.51. Long-Term Debt to Equity for the company is recorded at 12.90, with the Long-Term Debt to Total Capital now at 10.06.
Reflecting on the efficiency of the workforce at the company, Matinas BioPharma Holdings Inc. [MTNB] managed to generate an average of -$827,269 per employee.Matinas BioPharma Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 23.00 and a Current Ratio set at 23.00.
Matinas BioPharma Holdings Inc. [MTNB]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Matinas BioPharma Holdings Inc. posted -0.04/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MTNB.
An analysis of insider ownership at Matinas BioPharma Holdings Inc. [MTNB]
There are presently around $45 million, or 23.50% of MTNB stock, in the hands of institutional investors. The top three institutional holders of MTNB stocks are: BOXER CAPITAL, LLC with ownership of 11,478,634, which is approximately 0% of the company’s market cap and around 2.80% of the total institutional ownership; VIVO CAPITAL, LLC, holding 11,279,323 shares of the stock with an approximate value of $11.28 million in MTNB stocks shares; and VANGUARD GROUP INC, currently with $7.62 million in MTNB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Matinas BioPharma Holdings Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 20 institutional holders increased their position in Matinas BioPharma Holdings Inc. [AMEX:MTNB] by around 1,823,510 shares. Additionally, 21 investors decreased positions by around 4,091,884 shares, while 33 investors held positions by with 39,521,544 shares. The mentioned changes placed institutional holdings at 45,436,938 shares, according to the latest SEC report filing. MTNB stock had 7 new institutional investments in for a total of 130,687 shares, while 13 institutional investors sold positions of 3,224,355 shares during the same period.